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I Introduction and aims
Drug markets can be seen from the perspective 
of supply and demand. Market-related indicators, 
therefore, particularly administrative data, such as 
seizures, price, purity and drug-related offences, 
are used in most countries for assessment of the 
drug situation and policy evaluation. However, the 
illicit nature of drug markets limits data availability 
and interpretation.  Drug policy is also increasingly 
focused on reducing harm, so expanding the scope 
of the indicators monitored to better address 
market-related harms has been identified as a 
priority (Council Conclusions, 2013). The EMCDDA 
has developed a conceptual framework to provide 
coherence and maintain progress by improving 
quality of collection and reporting of existing 
data, extending the range of data collected, and 
enhancing analysis. These are illustrated here using 
the example of drug prices.
I Method
The process for elaborating the supply framework 
involved review of relevant published literature, 
internal consultation and expert engagement.
I Conceptual framework
The EMCDDA has been working on developing 
the existing supply indicators. These were initially 
conceptualised as covering drug markets, drug-
related crime and drug supply reduction. In light of 
developments in drug markets and supply activities, 
their wider impacts and in tackling the drivers and 
enablers of drug supply, the conceptual framework 
has been developed further and the three thematic 
areas broadened (Figure 1).
Within each thematic area, there are core data, 
which the EMCDDA has been or is beginning to 
collect on a regular basis. These core data include 
both quantitative and qualitative information, which 
can provide important context to help understand 
the routine data collections and additional 
information on the operation of the market. Some 
data sources may be analysed to provide insights 
under more than one indicator.
In addition, the EMCDDA collects a range of non-
routine data from a wide variety of sources, which it 
is seeking to expand further, drawing on a range of
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external expertise, periodical reports and research 
findings and also seeks to exploit new data sources, 
such as open source data from the surface and 
dark net. Each thematic area comprises different 
domains and a range of potential indicators within 
each domain (Figure 2). 
I The example of drug prices
Developing the supply side data infrastructure 
should give a better understanding of how drug 
markets operate. Producers, traffickers and 
sellers are seen as responding to price and risk. 
Increases in the risks of arrest, drug seizure or 
asset confiscation lead to smaller quantities of 
drugs being offered at any given price. The price 
itself is determined by the interaction of the supply 
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and demand curves, as captured in the standard 
economic market diagram (Figure 3). The supply 
curve can shift for reasons other than policy 
interventions; for example, a drought in Afghanistan 
may raise the farm-gate price of opium, which 
may have an effect on the price of heroin along the 
supply chain. 
A number of improvements have been introduced 
in recent years, including collection of price data 
beyond the retail market level to include wholesale 
and middle market. Since price fluctuations can 
be influenced by events at any point in the supply 
chain, the authors are exploring access to price 
data at drug source and importation levels, based 
on the prices and risk framework (Reuter and 
Kleiman, 1986). This will offer enhanced insight into 
the factors that influence price. Export prices would 
reflect shifts in supply from producer countries, 
the differences between export and import prices 
would indicate changes in trafficking and retail 
prices would be indicative of shifts in domestic 
supply.
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I Conclusions
The EMCDDA conceptual framework provides 
coherence to improvements in current approaches, 
and opens up additional opportunities for data 
collection and analysis, which over time will 
improve understanding of drug markets, harms 
and supply reduction activities and ultimately, 
policy responses. There are limitations to any one 
source of information but collecting a range of 
data and triangulating sources can contribute 
to understanding the complex and constantly 
changing drug markets landscape.
FIGURE 1 | EMCDDA drug supply monitoring system 
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A demand (D) curve maps the 
relationship between price (P) 
and the quantity (Q) consumers 
are willing to purchase. 
e supply (S) curve maps the 
relationship between price and 
the quantity that producers 
(distributors) are willing to provide.
FIGURE 3 | Effect of a shift in the drug supply curve (adapted from 
Caulkins and Reuter, 2010) 
FIGURE 2 | Thematic areas, domains and potential indicators 
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